POPULARITY
24 episodes with emerging therapies
13 episodes with emerging therapies
12 episodes with emerging therapies
11 episodes with emerging therapies
7 episodes with emerging therapies
12 episodes with emerging therapies
5 episodes with emerging therapies
5 episodes with emerging therapies
6 episodes with emerging therapies
5 episodes with emerging therapies
3 episodes with emerging therapies
5 episodes with emerging therapies
4 episodes with emerging therapies
3 episodes with emerging therapies
5 episodes with emerging therapies
6 episodes with emerging therapies
5 episodes with emerging therapies
3 episodes with emerging therapies
Hair loss affects millions of people, yet most conversations begin only after thinning becomes visible. In this episode of Innovate & Elevate, Sharon Kedar sits down with board-certified dermatologist and hair health expert Dr. Doris Day to explore why the future of hair health may depend on earlier intervention, better understanding, and new scientific breakthroughs. Together, they discuss the biology of hair loss, the role of scalp health, inflammation, hormones, and genetics, and the innovations that could transform how we prevent and treat hair loss in the years ahead. From today's most effective therapies to emerging technologies currently in development, this conversation offers a fascinating look at one of the fastest-evolving areas of healthy aging and human health innovation.This Episode Is For You If:- You're interested in the latest science of healthy aging, including how hormones, inflammation, scalp health, and nutrition influence hair growth.- You want to learn about emerging innovations, treatments, and technologies that could change the future of hair loss prevention and hair health.- You've noticed hair thinning, increased shedding, or changes in your hair and want to understand what may be driving it.Connect with Dr. Doris Day, MD:- LinkedIn: https://www.linkedin.com/in/drdorisday/- Instagram: https://www.instagram.com/drdorisday/Connect with Sharon:- Connect with Sharon on LinkedIn: https://www.linkedin.com/in/sharonkedar/- Learn more about Innovate and Elevate: https:// innovateandelevatepodcast.com- Join the newsletter to receive the latest episodes in your inbox: https://innovateandelevatepodcast.com/emailThe content shared in this episode is for informational purposes only and does not constitute medical, financial, or investment advice. Please seek guidance from your own qualified professionals before making decisions.Timestamps(00:00) Why Hair Loss Matters So Much(02:15) Scarring vs. Non-Scarring Hair Loss(04:44) The Importance of Early Intervention(07:57) Understanding Hair Growth Cycles(09:23) Stress, Hormones & Hair Shedding(11:18) Female Pattern Hair Loss Explained(12:26) Minoxidil, Supplements & Treatment Options(14:09) Lasers, PRP & Emerging Therapies(16:25) Why Scalp Health Matters(20:10) Protecting Hair Before It's GoneAdditional ResourcesHair Loss Treatments:Minoxidil (topical)Oral MinoxidilLow-Dose Naltrexone (LDN)PRP (Platelet-Rich Plasma)Supplements:NutrafolCurcumin (ingredient)Ashwagandha (ingredient)Saw Palmetto (ingredient)Vitamin D3 + K2Hair Devices & Technologies:Fotona HairLaseCurrentBody Hair Growth DeviceREVIANKeraFactorLaserCapCompanies & Research:Veradermics (time-release oral minoxidil company)RLX201 (experimental molecule discussed by Dr. Day)Rebooting the Biome (Dr. Day's book)About Our Guest: Dr. Doris Day, MD, is a board-certified dermatologist, Clinical Professor of Dermatology at NYU Langone Health, and founder of Day Dermatology and Aesthetics in New York City. A nationally recognized expert in skin, hair, scalp health, and healthy aging, she has been named one of Newsweek's Top Cosmetic Dermatologists in the United States and a Castle Connolly Top Doctor for more than 20 consecutive years. Dr. Day is also a bestselling author, educator, researcher, and Co-Founder of Rapalogix Health, where she helps advance innovative approaches to skin longevity and regenerative health.About Sharon: Sharon Kedar is a co-founder and partner at Northpond Ventures, a multi-billion-dollar science-driven venture capital firm. Sharon holds an MBA from Harvard Business School and is a CFA charter holder. She lives in the Washington, DC area with her husband, Greg, their three kids, and their dog Bo.This podcast is produced by Brave Moon Podcasts.FAQsWhy am I losing hair in midlife even though I'm otherwise healthy?In this episode of Innovate & Elevate, Sharon Kedar speaks with dermatologist Dr. Doris Day about why hair loss is often more complex than people realize. Dr. Day explains that genetics are only one piece of the puzzle. Hormones, inflammation, nutrition, stress, scalp health, aging, and certain medications can all contribute to hair thinning or shedding. Together, Sharon and Dr. Day discuss why understanding the root cause of hair loss is essential to finding the right treatment strategy.Can hair loss be prevented before it becomes noticeable?According to Dr. Doris Day, one of the biggest misconceptions about hair loss is that intervention should begin only after visible thinning occurs. In this episode, Dr. Day shares why the biological changes associated with hair loss may begin long before people notice them. Sharon and Dr. Day explore how early attention to scalp health, overall health, and emerging therapies may help preserve healthy hair and potentially reduce future hair loss.What are the most effective treatments for hair loss today?In this conversation, Dr. Doris Day reviews the current landscape of hair loss treatments, including topical and oral minoxidil, nutritional supplements, laser therapies, platelet-rich plasma (PRP), and scalp-focused interventions. Sharon and Dr. Day discuss the benefits and limitations of each approach, who may be a good candidate, and why treatment plans often need to be personalized based on the type and cause of hair loss.How does scalp health affect hair growth?Dr. Doris Day explains that healthy hair starts with a healthy scalp. In this episode, Sharon and Dr. Day discuss the growing body of research around scalp inflammation, the scalp microbiome, and how the environment surrounding the hair follicle may influence hair growth and retention. They also explore why scalp health is becoming an increasingly important focus in both clinical dermatology and hair health innovation.Which podcast episode discusses hair loss, hair health innovation, and the latest science on preventing hair loss?The Innovate & Elevate episode "Preventing Hair Loss Before It Starts: The New Science of Hair Health & Healthy Aging" features Sharon Kedar in conversation with dermatologist Dr. Doris Day. Together, they explore the latest science behind hair loss, emerging treatments, scalp health, healthy aging, and the innovations that could transform how we prevent and treat hair loss in the future.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter dives into the pharmacology of sleep, exploring where sleep medications fit within the broader framework of achieving healthy, restorative sleep. He explains why sleep is a biological imperative, why behavioral and environmental interventions must remain the foundation of good sleep, and how medications can serve as useful tools when carefully matched to a person's specific sleep problem. Peter examines the major classes of prescription sleep medications, including how they work, their effects on sleep architecture, their duration of action, side effects, and risks of tolerance and dependence. He also discusses the dangers of using sleep drugs without a clear understanding of the underlying problem being treated, the role of medications as short-term bridges during periods of acute stress, pain, or anxiety, and the promise that newer drugs like DORAs may hold for Alzheimer's prevention in high-risk individuals. Finally, Peter reviews the evidence for select off-label medications and supplements commonly used for sleep. We discuss: The biological foundations of sleep, the major drivers of sleep dysfunction, and the role sleep medications can play when appropriately matched to specific sleep problems [1:00]; Sleep hygiene, circadian alignment, and the medical causes of insomnia: building the foundation for effective sleep treatment [7:15]; Understanding insomnia: hyperarousal, CBT-I, paradoxical insomnia, and why different sleep problems require different treatments [12:45]; The difference between sedation and physiologic sleep: sleep architecture, restorative sleep stages, and matching medications to specific sleep problems [17:00]; Benzodiazepines for insomnia: mechanisms, effects on sleep architecture, and the risks of long-term use [18:45]; Z-drugs for insomnia: how Ambien, Sonata, and Lunesta work, and the ongoing risks of sleep medications targeting GABA systems [23:00]; Dual orexin receptor antagonists (DORAs) and the future of sleep medicine: orexin signaling, sleep architecture, and the emerging connection between sleep and Alzheimer's disease [27:15]; Melatonin for circadian timing: how timing signals differ from sedatives in the treatment of sleep disorders [36:30]; Trazodone for insomnia: preserving deep sleep while minimizing the risks of traditional sedative-hypnotics [42:00]; First-generation antihistamines for sleep: short-term sedation, anticholinergic risks, and concerns about long-term cognitive health [44:00]; Sleep supplements and the evidence behind them: glycine, magnesium, ashwagandha, phosphatidylserine, and more [45:45]; Takeaways: supplement quality, individualized sleep treatment, and the importance of matching interventions to the biology of insomnia [52:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
What is lacking in the care of your patients with myasthenia gravis? Find out how novel pathology-targeting therapies can meet unmet needs. Credit available for this activity expires: 5/19/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/what-lies-beneath-generalized-myasthenia-gravis-exploring-2026a1000fuh?ecd=bdc_podcast_libsyn_mscpedu
In this podcast, experts Adam Brufsky, MD, PhD; Kamel Abou Hussein, MD; and Priyanka Sharma, MD, FASCO, discuss personalizing care in early-stage triple-negative breast cancer (TNBC) and the evolving first-line strategies and their implications for downstream sequencing in metastatic TNBC.
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including: A brief overview of BTC and GEA Notable findings from a recent survey of healthcare professionals on BTC and GEA Case studies on recommended management of patients with BTC or GEA Emerging datasets of HER2-directed therapies in BTC and GEA affecting clinical practice Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA Key ongoing trials of HER2-directed therapies in BTC and GEA Presenters: Amit Mahipal, MD, MPH Chief, GI Medical Oncology Program Professor of Medicine Ruth and Goodman Endowed Chair in GI Oncology H Seidman Cancer Center and Case Western Reserve University Cleveland, Ohio Shubham Pant, MD Professor Department of Gastrointestinal Medical Oncology Department of Investigational Cancer Therapeutics, Division of Cancer Medicine MD Anderson Cancer Center Houston, Texas Link to full program:https://bit.ly/4ckcBrZ Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Brain science does not stand still. New research continues to reshape how we think about memory, prevention, nutrition, and lifelong cognitive health.In this special Brain Week 2026 episode of the Let's Talk Brain Health! Podcast, your hosts brought together a panel of experts across neurology, neuropsychology, nutrition, sensory therapies, and aging science to discuss what is new, what is promising, and what still needs more evidence.This conversation focuses on separating hype from science. You will hear where the strongest research is emerging, what early warning signs deserve more attention, and how everyday habits influence brain health across the lifespan.If you want to stay current on brain health science and understand what actions are worth your attention right now, this episode brings the latest updates directly from the experts.What You Will Learn in This EpisodeEarly brain health signals adults often overlookWhy prevention starts decades before symptoms appear How sleep, smell changes, and hearing loss connect to brain healthWhat new research says about the MIND diet and dementia riskWhy personalized risk reduction matters more than one-size adviceThe role of caffeine and nutrition in cognitive performanceWhat emerging research says about sensory stimulation and brain functionWhy following evidence over trends protects your brain healthKey Topics CoveredEarly Detection and PreventionLearn why subtle changes such as sleep disruption, smell loss, and metabolic health may signal future neurological risk and why early action matters.Cognitive Aging and Risk ReductionUnderstand how lifelong learning, education, and cognitive engagement build resilience against cognitive decline.Nutrition and Brain HealthExplore the latest findings on the MIND diet, anti-inflammatory nutrition, and emerging areas like mushrooms and metabolic health.Brain Performance and Fueling CognitionLearn how caffeine and metabolic health influence daily brain performance.Emerging Therapies and Brain StimulationHear updates on areas such as 40 Hz sensory stimulation and aromatherapy research, and where the evidence currently stands.Key TakeawaysBrain health is built across decades, not just later in life.Prevention science continues to strengthen around lifestyle factors such as cardiovascular health, hearing health, sleep quality, and nutrition.There is no single solution for brain health. Personal risk factors matter.Patterns matter more than perfection when it comes to brain-healthy habits. Following credible science helps protect you from misinformation.Earn FREE CEs Join the Learn at Pinnacle app to earn FREE CE Credit for listening to this episode!Featured Expert GuestsDr. Kellyann Niotis, MD – Preventive Neurology and The Institute for Neurodegenerative Diseases of Florida Dr. Mitchell Clionsky, Ph.D. – Clinical Neuropsychology and author of Dementia Prevention: Using Your Head to Save Your BrainMaggie Moon, MS, RD – Brain health nutrition and author of the MIND dietDr. Richard Gold, Ph.D. – 40 Hz sensory stimulation and applied neuroscience from Metta Mindfulness MeditationDr. Jenna Stedman, DCN – Performance nutrition at Master Nutrition LabPatricia Faust, MGS – Clinical aromatherapy and aging brain health at My Boomer BrainPrevious Podcast Episodes from Our PanelistsEpisode 58: Preventive Neurology: Brain Care Today to Protect Tomorrow with Dr. Kellyann Niotis, MDEpisode 3: Dementia Prevention: Using Your Head to Save Your Brain with Dr. Emily Clionsky, M.D. and Dr. Mitch Clionsky, Ph.D.Episode 42: The MIND Diet Update: A Scientific Approach for Brain Health & Dementia Prevention with Maggie Moon, MS, RD Episode 6: Brain Beats: How Sound Influences Cognition with Dr. Richard Gold, Ph.D.Episode 48: Enhancing Cognitive Performance Through Nutrition with Dr. Jenna Stedman, DCN Episode 36: Essential Oils for Brain Health: Insights From A Clinical Aromatherapist, Patricia Faust, MGS
On this week's This Week in Pharmacy (TWIRx), we explore how innovation, technology, and emerging therapies are reshaping pharmacy practice. From the growing influence of AI in medical information research, to the next generation of pharmacy management systems, and the expanding role of cell and gene therapies, this episode brings together industry leaders to discuss what's next for pharmacy. Special thanks to this week's sponsors Cardinal Health, Independent Pharmacy Cooperative (IPC), and Nested Knowledge for supporting the podcast. Segment 1 – AI & the Future of Medical Information with Nested Knowledge Nested Knowledge returns to TWIRx as we welcome back Keith Kallmes, Co-Founder of Nested Knowledge, for an update on how artificial intelligence is transforming the way healthcare professionals access and interpret medical information. Keith explains how AI-powered tools are improving evidence synthesis, systematic literature reviews, and clinical decision support, helping researchers and clinicians navigate the growing volume of medical literature while enabling faster, more reliable insights. Segment 2 – The Evolution of Pharmacy Management Systems with Outcomes Next, we're joined by Lou Ann Myers from Outcomes to discuss how pharmacy management systems are evolving beyond traditional dispensing. Modern pharmacies require integrated technology connecting billing, treatment planning, clinical tracking, inventory management, and revenue-generating services. Lou Ann shares why these systems must support both clinical services and business sustainability as pharmacies expand into value-based care and new service models. Segment 3 – Emerging Therapies with Cardinal Health In our final segment, we welcome Dr. Fran Gregory, PharmD, Vice President of Emerging Therapies (Cell & Gene, Biosimilars) at Cardinal Health, to discuss one of the most transformative areas in healthcare. Dr. Gregory explores the growing impact of cell and gene therapies and biosimilars, and what these innovations mean for pharmacists, health systems, and specialty pharmacy providers as the industry prepares for new challenges in distribution, access, and reimbursement. About TWIRx (This Week in Pharmacy) TWIRx is the flagship news and commentary podcast from the Pharmacy Podcast Network, delivering weekly insights on the business, technology, and policy shaping the pharmacy profession.
CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from
Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join Mike and Trey Farley of Farley Pool Designs as they welcome Denise from River Flow to explore the significant role of water in mental health and wellness. With a background in marine biology and psychiatry, Denise shares her journey and expertise on how water and immersion therapy can aid in addiction treatment, anxiety, and overall mental health. The episode delves into personal stories, including Denise's use of River Flow Pumps in her own pool for therapy and recovery. They discuss the benefits of current in pools, optimal pool design for mental wellness, and future trends in water therapy. The conversation highlights the multifaceted uses of pools for exercise, relaxation, and mental rejuvenation, aiming to inspire listeners to harness the therapeutic properties of water in their own backyards. Discover more: https://theorg.com/org/televero-health/org-chart/dr-denise-canchola https://www.linkedin.com/in/dr-denise-canchola-a5539724a/ https://www.farleypooldesigns.com/ https://www.instagram.com/farleydesigns/ https://www.instagram.com/luxuryoutdoorlivingpodcast/ https://www.instagram.com/poolzila/ 00:00 Introduction to Luxury Outdoor Living Podcast 01:17 Meet Our Guest: Denise's Journey and Expertise 04:02 The Healing Power of Water 10:12 Addressing Mental Health with Water Therapy 16:25 River Flow: A Game Changer in Water Therapy 21:09 Personal Stories and Benefits of Water Therapy 28:36 Innovative Uses of Water in Therapy and Rehabilitation 31:18 The Power of Water in Addiction Recovery 31:41 Therapeutic Properties of Water 32:14 Breaking the Cycle of Addiction 32:37 The Role of Water in Mindfulness and Centering 35:45 Telehealth and Water Therapy 38:21 Designing Wellness-Friendly Pools 45:56 Emerging Therapies and Mental Health 50:14 Creating Optimal Pool Environments 52:35 The Joy and Benefits of Water 56:17 Conclusion and Final Thoughts
How much do you know about new therapies for treating fibrosis in MASH and the patients who can benefit most from them? Credit available for this activity expires: 10/29/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003068?ecd=bdc_podcast_libsyn_mscpedu
In this powerful and eye-opening conversation, Leanne Woehlke sits down with Dr. Ruchir Gupta, a double board-certified pain specialist and founder of Mountain View Headache and Spine Institute, to explore the evolving world of chronic pain treatment and clinical research.Dr. Gupta shares his journey from anesthesiology into chronic pain medicine and research, highlighting why traditional approaches often fail and how emerging therapies like ketamine infusions and stem cell treatments offer new hope. Together, they discuss the importance of changing the language around "experimental" medicine, improving access to clinical trials, and educating patients and physicians about cutting-edge but underutilized treatments.They also tackle:The broken incentives in insurance-driven medicineHow to ethically introduce new treatments to patientsThe power of AI and EMRs in revolutionizing clinical trial recruitmentRebuilding trust in the medical system through transparency and educationThis episode is a must-listen for healthcare professionals, clinical researchers, and patients seeking alternatives to outdated treatments and a deeper understanding of how clinical research can drive real change in patient care.Dr Ruchir Gupta:Dr. Ruchir Gupta is a board-certified pain specialist and anesthesiologist with advanced training in chronic pain management from the Mayo Clinic's Alix School of Medicine in Arizona. A New York native, he completed medical school at Upstate Medical University in Syracuse and his anesthesiology residency at New York Medical College – St. Vincent's Hospital in Manhattan.With over 20 peer-reviewed publications and two medical textbooks to his name, Dr. Gupta blends cutting-edge Western medicine with holistic, nature-based therapies. His areas of expertise include interventional pain management, IV infusion therapy, bone marrow concentrate procedures, and regenerative orthopedics.Dr. Gupta is a member of several leading professional societies, including the American Society of Pain and Neuroscience and the American Headache Society. He currently practices in Mesa and Phoenix, Arizona, where he is also part of the elite Regenexx network of interventional orthopedic physicians.To connect with Dr Gupta:LinkedIn: https://www.linkedin.com/in/ruchir-gupta-3187326b/https://mountainviewheadacheandspine.com/
Can you recognize and manage immunoglobulin A nephropathy (IgAN)? Hear from patients and expert faculty on how breakthroughs in therapy could enhance patient outcomes. Credit available for this activity expires: 9/30/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/bridging-gap-case-based-exploration-current-and-emerging-2025a1000q1d?ecd=bdc_podcast_libsyn_mscpedu
CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-managing-adult-and-pediatric-patients-with-fsgs-latest-data/37186/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.
CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-managing-adult-and-pediatric-patients-with-fsgs-latest-data/37186/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.
Drs. Fava and Petri discuss emerging therapies in systemic lupus erythematosus, including treatments for lupus nephritis and cutaneous disease.
CME credits: 1.00 Valid until: 28-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-neuropsychiatric-symptoms-of-alzheimers-disease-early-recognition-diagnosis-and-innovative-emerging-therapies/35728/ Neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.=
CME credits: 1.00 Valid until: 28-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-neuropsychiatric-symptoms-of-alzheimers-disease-early-recognition-diagnosis-and-innovative-emerging-therapies/35728/ Neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.=
Summary In this truncated replay from a session at the 2025 SF Derm Annual Conference, Dr. Lawrence Eichenfield discusses the latest advancements in the treatment of atopic dermatitis, focusing on new topical and systemic therapies, the role of corticosteroids, and the evolving perspectives on patient care. He highlights the importance of understanding both the benefits and concerns associated with various treatments, including the impact of media on patient perceptions. Takeaways - We have new topical agents for atopic dermatitis. - Topical corticosteroids are like hammers for eczema. - Topical steroid addiction is a real concern. - We have lots of options for atopic dermatitis. - New non-steroidals are being approved for younger patients. - Dupilomab shows promise in remission data. - Topical care remains a cornerstone of treatment. - We need to defend topical corticosteroids. - Long-term safety data is crucial for new therapies. - Patients often fear topical steroid withdrawal. Chapters 00:00 - Introduction to Atopic Dermatitis Innovations 02:46 - Emerging Therapies for Atopic Dermatitis 04:33 - Topical Corticosteroids: Benefits and Concerns 08:30 - Understanding Topical Steroid Withdrawal 08:46 - New Non-Steroidal Treatments for Atopic Dermatitis
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/BPN865. CME/AAPA credit will be available until August 4, 2026.A New Era in GPP Treatment: Clinical Insights, Biomarkers, and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/targeting-cause-emerging-therapies-menopausal-vms-10267SummaryThis enduring podcast activity explores groundbreaking advancements in the treatment of menopausal vasomotor symptoms (VMS), emphasizing non-hormonal therapies. Dr. Andrea Singer and Dr. Genevieve Neal-Perry discuss the underlying biology of menopause, particularly the role of neurokinin (NK) receptors, and introduces the science behind new therapeutic agents, as well as their clinical trial data.This podcast was recorded and is being used with permission of the presenters.Learning ObjectiveDiscuss the clinical trial data for new and emerging non-hormonal therapiesThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
Today we'll focus on a major shift in the treatment of myasthenia gravis -- as a wave of new therapies is changing how we treat this disease. Who should be considered for these new treatments? And what else is in the pipeline? Our guest today is Dr. Gil Wolfe, a neuromuscular neurologist at the University of Buffalo State University of New York, Jacob School of Medicine and Biomedical Sciences. Dr. Wolfe was interviewed by Dr. Ioannis Karakis, adjunct professor of neurology at Emory University School of Medicine. References: https://www.nature.com/articles/s41598-024-79918-7 Disclosures: Dr. Wolfe discloses: Consultant for: Alexion, Argenx, BPL, Cartesian, Canopy, Grifols, Johnson & Johnson, Takeda, UCB; Speaker Bureau for: Grifols, Alexion, UCB; Grant/Research support from: ArgenX, Ra/UCB, Immunovant, Roche, Alexion, Sanofi
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
Drs. Socinski and Sabari discuss a couple of abstracts from ASCO 2025 about emerging therapeutics in small cell lung cancer.
In this episode of the Diabetes Innovators Series, Rob interviews Dr. Michael Riddell and discuss the latest innovations in diabetes management, particularly focusing on exercise, education, and emerging therapies. He emphasizes the importance of personalized approaches to diabetes care, the role of artificial intelligence in optimizing treatment, and the hope surrounding potential cures such as islet transplants. The discussion highlights the challenges faced by individuals with diabetes, the significance of education and support, and the exciting advancements in technology and medication that are shaping the future of diabetes management. Chapters 00:00 Intentionality in Diabetes Management 02:11 Innovations in Diabetes and Exercise 05:51 Education and Support for Exercise 09:35 Personalized Approaches to Diabetes Management 10:34 The Role of AI in Diabetes Care 12:50 Emerging Therapies and Medications 15:40 Hope for a Cure: Islet Transplants 17:20 The Impact of Technology on Diabetes Management 18:49 The Influence of Lifestyle Factors 20:52 Inhaled Insulin and Its Benefits Resources: Glucose Control During Physical Activity and Exercise Using Closed Loop Technology in Adults and Adolescents with Type 1 Diabetes by Dr. Riddell & Dr. Dessi Zaharieva Dr. Michael Riddell
⚡️Female-specific health protocols, groundbreaking therapies, & the secrets to thriving in your prime years.
⚡️Female-specific health protocols, groundbreaking therapies, & the secrets to thriving in your prime years.
Welcome to the Choosing Wisely Campaign series! This is the third episode of a 6-part series exploring the ABIM Foundation's Choosing Wisely Lists. This campaign aims to promote conversations between clinicians and patients to avoid unnecessary medical tests, treatments, and procedures. Our second case-based episode presents an infant with diarrhea and diaper dermatitis. After a clear discussion of the case and thoughtful consideration of the etiology and treatment strategies, we use the AAP's Choosing Wisely dermatology and gastroenterology, hepatology, and nutrition lists to create a resource-conscious care plan that is safe and patient-centered. In the coming episodes, we'll explore the pediatric lists and apply our knowledge to cases of common presentations seen in primary and acute care pediatrics. Series Learning Objectives: Introduction to the Choosing Wisely Campaign: Understand the origins, historical precedent, and primary goals of the campaign. Case-Based Applications: Explore five common presentations in primary and acute care pediatrics, applying concepts from various Choosing Wisely lists to guide management and resource stewardship. Effective Communication: Learn strategies for engaging in tough conversations with parents and colleagues to create allies and ensure evidence-based practices are followed. Modified rMETRIQ Score: 15/15 Competencies: AACN Essentials: 1: 1.1 g, 1.2f, 1.3de 2: 2.1 de, 2.2g, 2.4fg, 2.5 hijk 7: 7.2 ghk 9: 9.1ij, 9.2ij, 9.3ik NONPF NP Core Competencies: 1: NP1.1h, NP 1.2km, NP 1.3fjh 2: NP2.1jg, NP2.2kn, NP 2.4hi, NP2.5 klmno 7: NP7.2m 9: NP9.1mn, NP9.2n, NP9.3p References ABIM Foundation. (2019). Communicating about overuse with vulnerable populations. Retrieved from https://www.choosingwisely.org/files/Communicating-About-Overuse-to-Vulnerable-Population_Final2.pdf AAP Section on Dermatology. (2021). Five things physicians and patients should question. https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWDermatology.pdf AAP Section on Gastroenterology, Hepatology, and Nutrition. (2023). Five things physicians and patients should question. https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWGastroenterology.pdf Harriet Lane Service (Johns Hopkins Hospital), Anderson, C. C., Kapoor, S., & Mark, T. E. (2024). The Harriet Lane handbook: a manual for pediatric house officers (23rd ed.). Elsevier. Jauregui, J., Nelson, D., Choo, E., Stearns, B., Levine, A. C., Liebmann, O., & Shah, S. P. (2014). External validation and comparison of three pediatric clinical dehydration scales. PloS one, 9(5), e95739. https://doi.org/10.1371/journal.pone.0095739 Johnson, H., & Yu, J. (2022). Current and Emerging Therapies in Pediatric Atopic Dermatitis. Dermatology and therapy, 12(12), 2691–2703. https://doi.org/10.1007/s13555-022-00829-4 Semon, A. K., Keenan, O., & Zackular, J. P. (2021). Clostridioides difficile and the Microbiota Early in Life. Journal of the Pediatric Infectious Diseases Society, 10(Supplement_3), S3–S7. https://doi.org/10.1093/jpids/piab063
Drs. Zaman and Podolanczuk discuss data for new and emerging therapies for ILD presented at ATS 2025, including nerandomilast, inhaled therapies for IPF and ILD, TNIK inhibitors, as well as new biomarkers and imaging for diagnosing ILDs.
In this episode of the Radical Health Rebel podcast, Helen Taylor, shares her extensive journey in understanding the connection between gut health, hormonal imbalances, and skin conditions. Helen discusses her personal experiences with health challenges, the importance of holistic approaches to wellness, and the often-overlooked impact of diet and environmental toxins on skin health. The conversation delves into the gut-skin connection, the role of sugar and hormones, and the significance of addressing root causes rather than just symptoms in conventional medicine. In this conversation, Helen and Leigh delve into the evolving landscape of functional medicine, focusing on the intricate relationship between gut health and skin conditions. They discuss advanced testing methods, the importance of individualized treatment, and the impact of lifestyle changes on skin health. The conversation also highlights the role of toxicity in health issues, emerging therapies in gut and skin health, and effective detoxification techniques. They emphasize the need for a personalized approach to health, acknowledging the unique biochemical makeup of each individual.We discussed:00:00 Introduction to Gut Health and Personal Journey02:59 The Impact of Hormonal Imbalances06:02 Aging and Body Care08:57 The Gut-Skin Connection11:46 Understanding Skin Conditions15:03 The Role of Sugar and Hormones18:02 Toxins in Our Environment20:58 Overlooked Sources of Toxicity23:51 Conventional Medicine vs. Root Causes27:01 Finding Solutions to Skin Issues31:51 Exploring Advanced Testing Methods34:43 The Importance of Individualized Treatment36:44 Lifestyle Changes for Skin Health40:43 Understanding Toxicity and Its Effects44:42 Emerging Therapies in Gut and Skin Health49:33 Detoxification Techniques and Their Importance54:37 Addressing Fungal Overgrowth and Parasites58:39 Questioning Dietary Norms and Microbiome HealthYou can find Helen @:Website: http://thewellness-concierge.comFacebook: https://www.facebook.com/profile.php?id=61568193574841Instagram: https://www.instagram.com/thewellness_concierge/Send us a textSupport the showDon't forget to leave a Rating for the podcast!You can find Leigh @: Leigh's website - https://www.bodychek.co.uk/Leigh's books - https://www.bodychek.co.uk/books/ Chronic Pain Breakthrough Blueprint - https://bit.ly/ChronicPainValuableTips Substack - https://substack.com/@radicalhealthrebelYouTube Channel - https://www.youtube.com/@radicalhealthrebelpodcast Rumble Channel - https://rumble.com/user/RadicalHealthRebel Leigh's courses: StickAbility - https://stickabilitycourse.com/ Mastering Client Transformation (professional course) - https://www.functionaldiagnosticnutrition.com/mastering-client-transformation/ Eliminate Adult Acne Programme - https://eliminateadultacne.com/
In this episode of the Radical Health Rebel Podcast, I'm joined by Jason Ott for a powerful conversation exploring our personal journeys through chronic pain and healing. We dive deep into the limitations of conventional medicine and unpack the complex, multifaceted nature of chronic pain—highlighting the often-overlooked role of mental and emotional health in the healing process.Together, we discuss why a holistic approach is essential, the importance of mindset and awareness, and how subconscious patterns influence our health behaviors. We also explore emerging therapies, strategies for breaking the pain cycle, and the critical need to find purpose beyond simply alleviating pain. If you're ready to reclaim control over your health and well-being, this episode is for you.We discussed:00:00 Personal Journey and Health Background07:19 Understanding Chronic Pain12:22 The Impact of Personal Experience on Healing19:49 The Role of Mental and Emotional State25:56 Limitations of Conventional Medical Approaches34:52 The Mind-Body Connection in Healing44:20 Awareness and Mindset in Healing47:01 The Importance of Education and Understanding47:50 Mental State and Pain Perception50:03 Subconscious Influences on Behavior51:48 Feedback and Learning from Experiences52:46 Finding Purpose Beyond Pain56:07 The Role of Intentionality in Change59:03 Repetition and Positive Reinforcement01:00:52 Stepping Outside Comfort Zones01:05:55 Emerging Therapies for Chronic Pain01:13:56 Breaking the Pain Cycle01:17:58 Future Projects and Sharing StoriesYou can find Jason @:https://empoweredprevention.comSend us a textSupport the showDon't forget to leave a Rating for the podcast!You can find Leigh @: Leigh's website - https://www.bodychek.co.uk/Leigh's books - https://www.bodychek.co.uk/books/ Chronic Pain Breakthrough Blueprint - https://bit.ly/ChronicPainValuableTips Substack - https://substack.com/@radicalhealthrebelYouTube Channel - https://www.youtube.com/@radicalhealthrebelpodcast Rumble Channel - https://rumble.com/user/RadicalHealthRebel Leigh's courses: StickAbility - https://stickabilitycourse.com/ Mastering Client Transformation (professional course) - https://www.functionaldiagnosticnutrition.com/mastering-client-transformation/ Eliminate Adult Acne Programme - https://eliminateadultacne.com/
To subscribe to our podcast and YouTube channel visit: https://www.youtube.com/@davisphinneyfdn/podcasts In this episode, we're sharing an excerpt from our May 2025 Live Well Today webinar about Emerging Therapies for Parkinson's, which features Dr. Soania Mathur and Dr. Michael Okun. In this excerpt, Dr. Mathur and Dr. Okun discuss three emerging treatments for Parkinson's that are designed for continuous under-the-skin infusion. These treatments have all been found to increase the amount of time Parkinson's symptoms are well managed throughout the day. You can learn more about these and other emerging therapies by watching the entire May 2025 Live Well Today webinar recording. Watch the full webinar here: https://youtu.be/zqdXgoyVHT8 Medications discussed in this episode: Vyalev, the first 24-hour infusion of foslevodopa and foscarbidopa: https://davisphinneyfoundation.org/continuous-infusion-levodopa-approved-usa/ ONAPGO, an apomorphine infusion that offers rapid relief from OFF episodes: https://davisphinneyfoundation.org/continuous-infusion-apomorphine-approved/ And NeuroDerm ND0612, an investigational levodopa/carbidopa infusion, now in late-stage trials: https://neuroderm.com/our-solution/about/what-is-nd0612/ Season 6 Episode 9
In this powerful episode, Marnie and Stephanie sit down with Robby Besner, founder and Chief Science Officer of Therasage, to explore cutting-edge wellness tools designed to support detoxification, reduce pain, and boost vitality. Robby shares the personal journey that led him to create Therasage, sparked by his daughter's battle with chronic Lyme disease. From infrared saunas and red light therapy to PEMF (Pulsed Electromagnetic Field) technology, he breaks down the science behind these natural healing tools and how they help mobilize toxins, support circulation, and enhance overall well-being. You'll learn: How daily sauna use supports detox and immune health The key differences and benefits of red light vs. PEMF therapy Why mimicking nature's frequencies is essential for healing The emerging role of nitric oxide in vascular health How portable, affordable tech can empower your wellness journey Plus, for a limited time, enjoy 25% off sitewide at Therasage.com with code ARTOFLIVINGWELL — valid for 72 hours after this episode drops! Chapters 05:41 The Genesis of Therisage 12:51 Exploring Popular Wellness Products 26:40 Diving into Red Light Therapy 39:03 Understanding PEMF Technology 42:00 The Science Behind Pulsing Frequencies 46:04 Enhancing Blood Flow and Circulation 47:29 Comparing PEMF and Red Light Therapy 49:56 Emerging Therapies and Innovations 53:55 The Future of Health Technologies Helpful links and resources: https://therasage.com FB: https://www.facebook.com/Therasage IG: @therasageinfared --------------------------------------------------------- 7-Day Vitality Reboot: Start anytime! Revitalize your body and turn inward this winter with our self-guided 7-Day Vitality Reboot designed to leave you feeling refreshed, energized, and ready to embrace the season ahead! We now have a program where you can do it on your own schedule but still receive all the wonderful support and recipes of the full program. Register here! --------------------------------------------------------- Thanks to our amazing Sponsor, Good Health Saunas. Good Health Saunas is proud to provide top-of-the-line infrared saunas that deliver the most impactful results for overall health and wellness. For more information and for your special discount please visit, www.goodhealthsaunas.com and mention The Art of Living Well Podcast. --------------------------------------------------------- Thanks to our amazing Sponsor, ZBiotics ZBiotics Pre-Alcohol Probiotic is the world's first genetically engineered probiotic. It was invented by PhD scientists to tackle rough mornings after drinking. Just remember to drink ZBiotics before drinking alcohol, drink responsibly, and get a good night's sleep to feel your best tomorrow. ZBiotics is backed with 100% money back guarantee so if you're unsatisfied for any reason, they'll refund your money, no questions asked. Go to ZBiotics to get 15% off your first order when you use code AOLW at checkout. --------------------------------------------------------- Need more protein and energy in your day? Check out these amazing, high quality products from Kion, especially their essential amino acids, creatine and protein powders, which we both use daily. Use code 'ARTOFLIVING' for a discount off your purchase. ----------------------------------------------------------- Ask us a question/make a recommentation We'd love to hear from you! Click here to share your feedback and suggestions. ----------------------------------------------------------- Sign-up for your 15 minute Health Transformation Audit - Click here. ----------------------------------------------------------- Let us help you get to the root cause of your unwanted symptoms. Schedule a 15 minute consultation to discuss at-home functional medicine lab testing here. ----------------------------------------------------------- How can you support our podcast? Apple users, please subscribe and review our show on Apple Podcasts,we make sure to read them all. Android users, please be sure to subscribe to our show on Google Podcasts so that you don't miss any of the action. Tell a friend about The Art of Living Well Podcast® and our community programs. Share your favorite episode on social media and don't forget to tag us @theartofliving_well. Subscribe to our Youtube channel Shop our Favorite Products: https://www.theartoflivingwell.us/products Connect with us on social media: IG: @theartofliving_well FB: theartoflivingwell Get on our list so you don't miss out on announcements, programs and events. You can download our guests' favorite reads here. Learn more about your hosts: Marnie Dachis Marmet Stephanie May Potter
In this episode, we dive into the complexities of IgG4-Related Disease (IgG4-RD), a mysterious and multi-organ condition that continues to challenge both patients and physicians. Back in January 2024, Dr. John Stone introduced us to the emerging landscape of treatments for IgG4-RD, and today, Dr. Matthew Baker joins us to provide an exciting update. With new therapies on the horizon, we explore the role of B and T cell pathogenesis, the limitations of traditional steroid treatments, and the off-label use of rituximab. We also take a closer look at the promising results from the “Mitigate Trial,” which offers hope for future strategies in managing this enigmatic disease. Join us as we discuss the evolving treatment landscape and what lies ahead for those affected by IgG4-RD.
Eva Feldman, MD, PhD, joins us this week to examine recent research on individuals in academic medicine who felt unprepared for leadership responsibilities, and she helps us explore ways to better prepare faculty for success in those positions. With Michigan Medicine in Ann Arbor, Dr. Feldman is the James W. Albers Distinguished University Professor and Russell N. DeJong Professor of Neurology. She also serves as Professor of Neurosurgery and is the Director of the NeuroNetwork for Emerging Therapies and the ALS Center of Excellence at Michigan Medicine. “I would say that my main takeaway is this: if you are a mid-level professional aspiring to a leadership position, seek a mentor and sponsor immediately, and ensure you are trained to be ready for that role,” Dr. Feldman told us. The article she co-authored, titled “Leadership Experiences and Perceptions of Mid-Career to Senior Clinician-Scientists: A Qualitative Exploration,” highlighted key leadership challenges and opportunities that we explore in-depth with Dr. Feldman in this interview. You can learn more about the report here: https://journals.lww.com/academicmedicine/abstract/9900/leadership_experiences_and_perceptions_of.877.aspx?utm_source=sfmc&utm_medium=email&utm_campaign=amexpress&utm_content=newsletter You can also visit FacultyFactory.org here: https://facultyfactory.org/
In this episode of The Syneos Health Podcast, we continue our exploration of Project Optimus and the evolution of dose optimization in oncology drug development. Following our discussion on regulatory expectations in the previous episode, we now turn to the operational challenges and strategies required to implement optimized dosing in real-world settings.Host Dr. Wael Harb is joined by Patrick Melvin, Vice President, Oncology & Hematology and Global Head, Novel and Emerging Therapies at Syneos Health, to discuss the complexities of operationalizing Project Optimus. Together, they examine how drug developers, investigator sites and patients are affected by these changes, the role of adaptive study designs, and how AI-driven technologies and digital health innovations are helping to streamline dose optimization.Tune in to gain valuable insights into the future of precision dosing and the long-term benefits of this industry shift, from improving patient outcomes to enhancing drug development efficiency.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.
This guideline was created as an educational tool to guide qualified physicians through a series of diagnostic and treatment decisions to improve the quality and efficiency of care for adult patients with Brain Metastases treated with Laser Interstitial Thermal Therapy (LITT). J. Bradley Elder, MD Mark E. Linskey, M.D., FAANS Kristin Huntoon, PhD, DO Brandon Lucke-Wold, MD, PhD
Dr. Tania Small joined Bristol Myers Squibb as Senior Vice President, Global Medical Affairs in January 2024. Tania brings a strong scientific track record leading Medical Affairs teams in driving innovation that improves the experience and supports better outcomes of people living with cancer and rare diseases. She has successfully built and led global and regional medical organizations in Drug Development and Medical Affairs, advancing access to Oncology, Rare Disease and Hematology patients globally.Tania is a board-certified pediatric hematology, oncology, and bone marrow transplant specialist with deep experience in clinical research and drug development. She has extensive research experience in oncology, hematology, gene therapy and stem cell transplantation, receiving NIH grants for her translational research in gene therapy and regenerative medicine.Most recently, Tania served as Head of Global Medical Oncology and was the sponsor of the Global R&D Inclusion Diversity Council at GSK. Prior to GSK, Tania worked for IPSEN as Vice President, Head of Oncology and Rare Disease Global Drug Development.She is energized by revolutionizing the experience and outcomes for people with cancer, and has worked closely with the US FDA, Congress, and the American Society of Clinical Oncology (ASCO) to improve the diversity of enrollment in oncology clinical trials and elderly programs."I'm passionate about partnering to create programs that treat the person - not just the disease. Producing groundbreaking solutions that can change the trajectory of serious diseases and help write the next chapter of patient-driven science is what motivates me every day."Tania received her medical degree from Albert Einstein College of Medicine. She has a long-standing affiliation with the Morgan Stanley Children's Hospital of New York Presbyterian/Columbia University where she completed her residency and hematology/oncology fellowship with an academic research appointment in heme and bone marrow transplant.Currently, Tania serves on the ASCO Membership Advisory Committee and is a Board Member of Accreditation Council for Medical Affairs (ACMA).
Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease. I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida. Our full disclosures are available in the transcript of this episode. James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary. But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting. So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important. Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission. In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults. I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate. The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it. The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting. The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work. Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved. One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now. So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field. Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it. And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't. A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that. I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results. There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that. John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets. I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can. I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that. And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. John Sweetenham Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. John Sweetenham: No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview
In this episode, Dr. G dives deep into the fascinating science of mitochondrial health—your body's ultimate power source. Learn how these tiny cellular powerhouses influence energy, immunity, aging, and overall well-being. Discover actionable steps to optimize your mitochondria and unlock your vitality, all while understanding the connections between nutrition, exercise, and environmental factors. #health #energy #wellness === Thank You To Our Sponsors! Puori Click here https://puori.com/drg and use code DRG for 20% off the already discounted subscription prices. SiPhox Health Visit siphoxhealth.com/healthyself to get 20% off your first at-home blood test and start your journey toward optimal health. === Show Notes: 00:00:30 - Welcome to Heal Thyself 00:00:48 - Understanding Mitochondria and Aging 00:01:06 - The Role of Mitochondria in Energy and Immunity 00:01:47 - Importance of Mitochondria for Overall Health 00:02:15 - Mitochondria: Powerhouses of the Cell 00:03:03 - Mitochondria's Functions Beyond Energy Production 00:04:25 - Analogy: Mitochondria as a Power Plant 00:05:05 - Mitochondria's Connection to Cancer 00:07:07 - Factors Disruptting Mitochondrial Health 00:09:44 - Join the Dr. G Healys Health Community 00:10:12 - Environmental Disruptors Affect on Mitochondria 00:10:44 - Understanding Mitochondrial Vulnerability to UV Radiation 00:11:05 - The Impact of Diet on Mitochondrial Function 00:11:24 - Key Nutrients for Mitochondrial Health 00:11:38 - The Role of Hormones in Mitochondrial Biogenesis 00:11:58 - The Effects of Stress on Mitochondrial Function 00:12:54 - Exploring the Connection Between Trauma and Mitochondrial Dysfunction 00:13:55 - Importance of Mitochondrial Autophagy 00:14:35 - Enhancing Lifespan Through Mitophagy 00:15:21 - Exercise as a Key Factor for Mitochondrial Health 00:16:06 - Nutritional Strategies to Support Mitochondria 00:17:02 - Emerging Therapies for Mitochondrial Optimization 00:18:10 - The Role of Sleep in Mitochondrial Function 00:19:05 - Managing Stress for Better Mitochondrial Health 00:20:09 - Recap: Key Factors Influencing Mitochondrial Health 00:20:40 - Actionable Steps to Improve Mitochondrial Function 00:21:10 - Upcoming Topic: Circadian Rhythms and Health 00:21:16 - Closing Remarks and Call to Action
© 2020-2026 Ivy Podcast Discovery LLC
